Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Neuroendocrine Tumors - Patient Reported Outcomes
Clinical trial update on patient-reported outcomes for neuroendocrine tumors in the NCT05064150 study sponsored by the University of Iowa; t…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) [Phase 1]
Phase 1 clinical trial evaluating the combination of SVV-001 with nivolumab and ipilimumab in patients with poorly differentiated neuroendoc…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors [Phase 1]
Phase I clinical trial update evaluating dose, pharmacokinetics, and safety of Lutetium-177-edotreotide therapy in pediatric participants wi…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 [Phase 1]
Phase 1 study evaluating different doses of BI 764532 in DLL3-positive small cell lung cancer and other neuroendocrine tumors; the trial is …
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: CapTemY90 for Grade 2/3 NET Liver Metastases [Phase 2]
A Phase 2 clinical trial evaluating CapTemY90 for liver metastases from neuroendocrine tumors (Grade 2) is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions
Clinical trial update on recruiting for a study evaluating endoscopic ultrasound-guided radiofrequency ablation of upper gastrointestinal tr…
-
EMA approval · 2025-12-08EMA Authorised: Xermelo (telotristat etiprate) — SERB SAS
EMA authorised Xermelo (telotristat etiprate) for the treatment of carcinoid syndrome–related diarrhea in adults with neuroendocrine tumors,…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN [NA]
A clinical trial is evaluating PET imaging with zirconium-labelled girentuximab in patients with hepatocellular carcinoma, intrahepatic chol…
-
FDA approval · 2025-12-05FDA Approved: ILLUCCIX — Supplemental Application (Telix Pharmaceuticals (US) Inc.)
FDA approves a supplemental application for ILLUCCIX, a kit for preparing gallium-68 gozetotide injection used in PET imaging. This marks an…
-
EMA approval · 2025-12-04EMA Authorised: Sunitinib Accord (sunitinib) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Sunitinib Accord for the treatment of gastrointestinal stromal tumors, renal cell carcinoma, and ne…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery [NA]
This clinical trial update describes a study comparing opioid-free and opioid-sparing anesthesia with opioid-based anesthesia in colorectal …
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors [Phase 2]
This Phase 2 clinical trial update reports recruitment for an alternative cabozantinib dosing schedule in metastatic renal cell carcinoma an…
-
CLINICAL_TRIALS research · 2025-11-13Clinical Trial Update: RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
RegisterNET is a registry for neuroendocrine tumors in the USA and worldwide. It is currently enrolling by invitation.
-
EMA approval · 2025-11-12EMA Authorised: Lutathera (lutetium (177Lu) oxodotreotide) — Advanced Accelerator Applications
European Medicines Agency authorized Lutathera (lutetium (177Lu) oxodotreotide) for neuroendocrine tumors; the product is designated as an o…
-
CLINICAL_TRIALS research · 2025-11-12Clinical Trial Update: Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
An ongoing NCI-sponsored observational study to collect tissue samples and characterize the natural history of neuroendocrine neoplasms, inc…
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors [EARLY_Phase 1]
Early-phase safety study of the radiopharmaceutical 212Pb-VMT-alpha-NET in patients with neuroendocrine tumors is active but not currently r…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors [Phase 1]
Phase 1 trial evaluating the addition of Triapine to Lutetium-177 dotatate radioligand therapy for metastatic neuroendocrine tumors; results…
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. [Phase 1, Phase 2]
A Phase 1/2 trial evaluating BXCL701 in combination with pembrolizumab for metastatic castration-resistant prostate cancer with small cell n…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating a Gallium-68 labeled FAPI tracer (Ga-FAPI-04) PET/CT for imaging patients with high-grade neuroen…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit [Phase 1]
Phase 1 study evaluating NN3201, a c-Kit targeted antibody-drug conjugate, in advanced and/or metastatic solid tumors expressing c-Kit; curr…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial) [Phase 3]
Phase 3 trial PReCedeNT comparing PRRT alone versus PRRT with chemotherapy for gastroenteropancreatic neuroendocrine tumors is currently rec…
-
FDA approval · 2025-09-11FDA Approved: ILLUCCIX — Supplemental Application (Telix Pharmaceuticals (US) Inc.)
FDA approved a supplemental application for ILLUCCIX, a kit for the preparation of gallium-68 gozetotide injection, for use in PET imaging o…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. [Phase 3]
This clinical trial update indicates a Phase 3 study of systemic targeted adaptive radiotherapy for neuroendocrine tumors, currently recruit…
-
CLINICAL_TRIALS trial_result · 2025-09-05Clinical Trial Update: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs [Phase 3]
A Phase 3 clinical trial compares Lutetium-177Lu oxodotreotide with Octreotide LAR in patients with gastroenteropancreatic neuroendocrine tu…
-
CLINICAL_TRIALS research · 2025-09-03Clinical Trial Update: Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab in combination with liver-directed therapy or peptide receptor radionuclide therapy for neur…